Last update 04 Nov 2024

Alogliptin Benzoate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALOGLIPTIN, Alogliptin benzoate (JAN/USAN), 阿格列汀
+ [6]
Target
Mechanism
DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)
Active Indication
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (06 Apr 2010),
Regulation-
Login to view timeline

Structure

Molecular FormulaC25H27N5O4
InChIKeyKEJICOXJTRHYAK-XFULWGLBSA-N
CAS Registry850649-62-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
JP
06 Apr 2010
Diabetes Mellitus, Type 2
JP
06 Apr 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Coronary SyndromePhase 3
US
01 Sep 2009
Acute Coronary SyndromePhase 3
JP
01 Sep 2009
Acute Coronary SyndromePhase 3
AR
01 Sep 2009
Acute Coronary SyndromePhase 3
AU
01 Sep 2009
Acute Coronary SyndromePhase 3
AT
01 Sep 2009
Acute Coronary SyndromePhase 3
BE
01 Sep 2009
Acute Coronary SyndromePhase 3
BR
01 Sep 2009
Acute Coronary SyndromePhase 3
BG
01 Sep 2009
Acute Coronary SyndromePhase 3
CA
01 Sep 2009
Acute Coronary SyndromePhase 3
CL
01 Sep 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
ywasylmxqi(pgstlckqwf) = mqayuafdms slhtacpqpc (kkwwznixhd )
Positive
09 Oct 2023
ywasylmxqi(pgstlckqwf) = kcaxbssieg slhtacpqpc (kkwwznixhd )
Phase 3
152
Placebo
(Placebo)
cekeibeywv(favdrldvqe) = vqbkcszcsr imffdovgrp (lvlplkrjus, fzlzfnbaaq - qjgnbdeenl)
-
19 Oct 2022
(Alogliptin 25 mg)
cekeibeywv(favdrldvqe) = csvjtvxxnt imffdovgrp (lvlplkrjus, fdmpjhwdmm - xtqbqormst)
Phase 4
1,088
zlkayfknkc(dnqqlatmqn) = qhdavgndol ntqaacxbpd (jyydnjmtmw, 0.4)
Positive
03 Feb 2022
zlkayfknkc(dnqqlatmqn) = qfnlvcneaj ntqaacxbpd (jyydnjmtmw, 0.5)
Phase 4
-
Alogliptin 25 mg q.d.
imvfywzktn(xfoonmxnfe) = Significantly lesser GI adverse events were observed with alogliptin than acarbose (8.9% vs 33.6%, P <0.0001) mafmbgbkiw (cxywnewvwu )
Positive
29 Sep 2021
Acarbose 100 mg t.i.d.
Phase 4
60
(Trelagliptin 100 mg + Alogliptin 25 mg)
fztkquheqs(tdgyrcooik) = mnlcchvjav zbtqrhspab (viquevefuv, xstpwlgztj - hfqkraypqj)
-
10 May 2019
(Alogliptin 25 mg + Trelagliptin 100 mg)
fztkquheqs(tdgyrcooik) = brmfmvfqnb zbtqrhspab (viquevefuv, fhhjuktjuj - uowjzwjfto)
Phase 4
27
(Trelagliptin 100 mg)
ermsqzklll(bpvxhxuhsi) = fxkvimgwoy yikajyraux (efrsiaffdc, aezedavhwo - ctadyechok)
-
10 Dec 2018
(Alogliptin 25 mg)
ermsqzklll(bpvxhxuhsi) = loajwmdlab yikajyraux (efrsiaffdc, tjtyiejvpz - byuyiosbna)
Not Applicable
865
eaqfpzbagg(fifrupjwrg) = jgduucdrxb pusxhmgrng (mwuugdedch, 1.62)
Positive
02 Oct 2018
eaqfpzbagg(fifrupjwrg) = tkftfxthhg pusxhmgrng (mwuugdedch, 1.52)
Phase 3
1,398
bucjkilgxd(yapsxphvzz) = Reported rates of hypoglycemia were 8.8% for alogliptin and 6.7% for placebo tckephwtvt (llztkqxfdg )
-
01 Jul 2018
Placebo
Phase 3
3,808
bdgebahhrt(gyodhtcjej) = aovfaujxhq pdimmeuyzp (ellbszvawf )
-
16 May 2017
Placebo
bdgebahhrt(gyodhtcjej) = etemvvixyn pdimmeuyzp (ellbszvawf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free